Voriconazole: therapeutic review of a new azole antifungal

Reference

• Chandrasekar HP, Manavathu E. Voriconazole: a second generation triazole. Drugs Today. 37, 135–148 (2001).
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur. J. Med. Res.7, 242–256 (2002).
   Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbial. 36, 198–202 (1998).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF and the Dutch Interuniversity Working Party for Invasive Mycoses. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.1. Clin. Microbial. 40, 2648–2650 (2002).
   PubMed Web of Science ®Google Scholar
• Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40, 1948–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42, 161–163 (1998).
   PubMed Web of Science ®Google Scholar
• Florea NR, Kuti JL, Quintiliani R. Voriconazole: a novel antifungal agent. Formulary 37, 1–10 (2002).
   Google Scholar
• Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs 11(3), 409–429 (2002).
   Google Scholar
• Cuenca-Estrella M, Dfaz-Guerra TM, Mellado E, Monzón A, Rodrfguez-Tudela JL. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur. J. Clin. Microbial Infect. Dis. 18, 432–435 (1999).
   PubMed Web of Science ®Google Scholar
• Pearson MM, Rogers PD, Cleary JD, Chapman SW Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37, 420–432 (2003).
   PubMed Web of Science ®Google Scholar
• Abraham OC, Manavathu EK, Cutright JL, et al. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbial Infect. Dis. 33, 7–11 (1999).
   PubMed Web of Science ®Google Scholar
• Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbial. 37, 2343–2345 (1999).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report of the SENTRY Antimicrobial Surveillance Program 2000. Antimicrob. Agents Chemother. 46, 1032–1037 (2002).
   PubMed Web of Science ®Google Scholar
• •Assessment of in vitro activity of majorbroad-spectrum antifungal agents on aspergillus.
   Google Scholar
• Pfaller M. Sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. 6th Candida and Candidosis Conference. Am. Soc. Microbial. (2002) (Abstract S6–S8).
   Google Scholar
• Patterson BE, Coates PE. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) (Abstract F78).
   Google Scholar
• Schwartz S, Milatovic D, Theil E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 97, 663–665 (1997).
   PubMed Web of Science ®Google Scholar
• Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12, 2227–2241 (1998).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Brinkman K, Kremer HP, Kullberg B, Meis JF. Aspergillus meningitis: diagnosis by noncuhure-based microbiological methods and management. J. Clin. Microbial. 37, 1186–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Muijsers RBR, Goa KL, Scott U. Voriconazole in the treatment of invasive aspergillosis. Drugs 61, 1–10 (2001).
   Google Scholar
• Food and Drug Administration. Background document for the antiviral drug products advisory committee meeting. Voriconazole tablets and injection, Pfizer Global Research and Development, NDAs 21–266 and 21–267. Food and Drug Administration Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products. 4 October 2001.
   Google Scholar
• Tomaszewski K, Purkins L. The pharmacokinetics (PK) and safety of sulfobutylether-B-cyclodextrans. Program and abstracts ofthe 41st Interscience Confirance on Antimicrobial Agents and Chemotherapy. Am. Soc. Microbial (2001) (Abstract A23).
   Google Scholar
• Sanches S, Najvar L, Bocanegra R, Graybill J. Efficacy of voriconazole in a guinea-pig model of systemic C albicans infection caused by isolates with elevated fluconazole MIC values. Program and abstracts of the 38th Interscience Confirence on Antimicrobial Agents and Chemotherapy (1998) (Abstract J78).
   Google Scholar
• Reyes GH, Long L, Hossain M, Ghannoum MA. Efficacy of voriconazole in the treatment of hematogenously disseminated Candida glabrata in a neutropenic guinea-pig model. Program and Abstracts of the 38th Interscience Confirence on Antimicrobial Agents and Chemotherapy (1998) (Abstract J62).
   Google Scholar
• Ghannoum MA, Okogbule-Wonodi I, Bhat N, Sanati H. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in a neutropenic guinea-pig model. J. Chemother. 11, 34–39 (1999).
   Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, RinaMi MG, Patterson TF. Efficacy of voriconazole in a guinea-pig model of disseminated invasive aspergillosis. Antimicrob. Agents Chemother. 44, 2865–2868 (2000).
   PubMed Web of Science ®Google Scholar
• Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with aspergillus. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) (Abstract F74).
   Google Scholar
• Chandrasekar PH, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. 45, 673–676 (2000).
   PubMed Web of Science ®Google Scholar
• Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus filmigatus endocarditis in guinea-pigs. Antimicrob. Agents Chemother. 41, 13–16 (1997).
   PubMed Web of Science ®Google Scholar
• Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41, 696–698 (1997).
   PubMed Web of Science ®Google Scholar
• George D, Miniter P, Andriole VT. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40, 86–91 (1996).
   PubMed Web of Science ®Google Scholar
• •Rabbit model demonstrating the efficacy of voriconazole in pulmonary aspergillosis.
   Google Scholar
• Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) (Abstract F75).
   Google Scholar
• Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33, 23–32 (1996).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud E Milpied N, et al Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infict. Dis. 34, 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• •Large open label study showing clinical efficacy in invasive aspergillosis.
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med. 347, 408–414 (2002).
   PubMed Web of Science ®Google Scholar
• •Randomized, comparative study demonstrating superiority of voriconazole over amphotericin B in invasive aspergillosis.
   Google Scholar
• De Pauw B. Clinical potential and experience of voriconazole. Clin. Microbial Infict. 5\(Suppl. 3) (1999) (Abstract 7).
   Google Scholar
• Schlamm HT, Corey L, Brown J, et al Voriconazole for salvage treatment of invasive aspergillosis. Clin. Infict. Dis. 31, 265 (2000) (Abstract).
   Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240–248 (2002).
   PubMed Web of Science ®Google Scholar
• •Report of the efficacy of voriconazole invarious fungal infections in children.
   Google Scholar
• Green BA, Lawrence C, Marr KA. Voriconazole for salvage therapy of fungal infection in patients with hematological malignancies and stem cell transplantation. Program and Abstracts of the 38th Annual Meeting of the Infictious diseases Society of America (2000) (Abstract 41).
   Google Scholar
• Van T'Hek LG, Verweij PE, Weemaes CM, Van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am. J. Re.vtir Crit. Caw Med. 157, 1694–1696 (1998).
   PubMedGoogle Scholar
• De Sevaux RG, Kullberg BJ, Verweij PE, et al Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. Clin. Infect. Dis. 26, 996–997 (1998).
   PubMed Web of Science ®Google Scholar
• Bielorai B, Toren A, Wolach B, et al Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 26, 1025–1028 (2000).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Asp ergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J. Clin. Microbial. 38, 3900–3901 (2000).
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 1447–1454 (2001).
   PubMed Web of Science ®Google Scholar
• •Shows that voriconazole is as effective as fluconazole in esophageal candidiasis.
   Google Scholar
• Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41, 575–577 (1997).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36, 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• •Details the activity of voriconazole in various severe invasive fungal infections.
   Google Scholar
• Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the USA and Africa. Anti microb. Agents Chemother. 43, 169–171 (1999).
   PubMed Web of Science ®Google Scholar
• Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. OphthalmoL 84, 932–933 (2000).
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR Lutsar I. Voriconazole for the treatment of S. apiospermum and S. prolzficans infection. Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (2000) (Abstract 305).
   Google Scholar
• Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin. Infect. Dis. 30, 981–982 (2000).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. _J. Clin. Microbial 36, 1436–1438 (1998).
   PubMed Web of Science ®Google Scholar
• Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. 27, 1437–1441 (1998).
   PubMed Web of Science ®Google Scholar
• Munoz P, Mann M, Tornero P, Rabadan PM, Rodriguez-Creixens M, Bouza E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. 31, 499–501 (2000).
   PubMed Web of Science ®Google Scholar
• Nesky MA, McDougal EC, Peacock JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31, 673–677 (2000).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Lutsar I, Gonzalez-Ruiz A. Voriconazole for the treatment of resistant and rare fungal pathogens. Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (2000) (Abstract 303).
   Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J. Med. 346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• •Large randomized study comparing voriconazole and liposomal amphotericin B for the empiric therapy of persistent febrile neutropenia.
   Google Scholar
• Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. MycoL 39, 19–95 (2001).
   PubMedGoogle Scholar